A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125I Seed Implantation Plus Apatinib After Surgery

Niu, Yiqi; Ding, Zheng; Deng, Xianzhao; Guo, Bin; Kang, Jie; Wu, Bo; Fan, Youben

doi:10.3389/fendo.2020.00207

Cited by 10 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are case reports, describing the pre- (30) and postoperative (31) use of the selective VEGFR-2/SRC inhibitor apatinib in single patients, but no clinical studies have thus far been published.…”

Section: Resultsmentioning

confidence: 99%

Anaplastic thyroid cancer: genome-based search for new targeted therapy options

Hescheler

Hartmann

Riemann

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

Objective: Anaplastic thyroid cancer (ATC) is one of the most lethal human cancers with meager treatment options. We aimed to identify targeted drugs already approved by the FDA for solid cancer in general, which could be effective in ATC. Design: Database mining. Methods: FDA-approved drugs for targeted therapy were identified by screening databases of MyCancerGenome and National Cancer Institute. Drugs were linked to target genes by querying Drugbank. Subsequently, MyCancerGenome, CIViC, TARGET and OncoKB were mined for genetic alterations which are predicted to lead to drug sensitivity or resistance. We searched the Cancer Genome Atlas database (TCGA) for patients with ATC and probed their sequencing data for genetic alterations which predict a drug response. Results: 155 FDA-approved drugs with 136 potentially targetable genes were identified. 17 (52%) of 33 patients found in TCGA had at least one genetic alteration in targetable genes. The point mutation BRAF V600E was seen in 45% patients. PIK3CA occurred in 18 % of cases. Amplifications of ALK and SRC were detected in 3% of cases, respectively. 15% of patients displayed a co-mutation of BRAF and PIK3CA. Besides BRAF-inhibitors, the PIK3CA-inhibitor copanlisib showed a genetically predicted response. The 146 (94%) remaining drugs showed no or low (under 4% cases) genetically predicted drug response. Conclusions: While ATC carrying BRAF mutations can benefit from BRAF-inhibitors and this effect might be enhanced by a combined strategy including PIK3CA-inhibitors in some of the patients, alterations in BRAF wild-type ATC are not directly targeted by currently FDA approved options.

show abstract

Section: Resultsmentioning

confidence: 99%

Anaplastic thyroid cancer: genome-based search for new targeted therapy options

Hescheler

Hartmann

Riemann

et al. 2022

Endocrine Connections

View full text Add to dashboard Cite

show abstract

“…[ 32 , 33 ] Of note, previous studies from our hospital also found that apatinib had better efficacy, a more manageable safety profile and faster therapeutic responses. [ 9 , 34 ]…”

Section: Discussionmentioning

confidence: 99%

“…Recent clinical trials have revealed its hopeful anticancer effect in various solid tumors, [ 7 , 8 ] and a similar result in TC was found in our team's previous research. [9] Herein, we report a case of a locally advanced inoperable DTC patient who underwent complete safe removal after undergoing preoperative short term apatinib targeted treatment, with little drug-related side effects and almost no postoperative complications.…”

Section: Introductionmentioning

confidence: 99%

Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer

et al. 2021

Self Cite

View full text Add to dashboard Cite

Rationale: Though the majority of differentiated thyroid cancer (DTC) patients have a good prognosis after careful and standardized therapy, approximately 13% to 15% of DTC cases show surprisingly aggressive behavior and invasion of the surrounding structures, and a few progress to unresectable diseases. In this study, we report a case of an inoperable locally advanced DTC patient who underwent a curative operation after treatment of preoperative monotherapy of apatinib in a short time. Patient concerns: A 64-year-old woman complained of dysphagia due to large cervical mass, which severely invaded the left esophagus at the junction of the neck and thorax. Diagnoses: The female patient was diagnosed with locally advanced papillary thyroid cancer (PTC) by cytopathology and it was difficult to perform a safe and complete removal. Interventions: Apatinib (500 mg orally once a day) was initially used to treat this patient as a neoadjuvant therapy. Outcomes: Six weeks later, the tumor dramatically shrunk from 56 × 37 mm to 29 × 26 mm with well-controlled mild hypertension. After a 10-day interval of apatinib withdrawal, complete tumor excision was accomplished through cervical incision without esophageal fistula. Postoperative thyroid stimulating hormone suppression and radioiodine 131 I ablation therapy were performed. At the 1-year follow-up evaluation, no tumor recurrence or metastasis was observed. Lessons: Preoperative short term targeted treatment with apatinib for locally advanced inoperable DTC may become a promising neoadjuvant therapy that, can reduce the tumor size and decrease stage, thus making the complete and safe removal of the lesion feasible.

show abstract

“…This scheme can be proven to be a feasible alternative treatment for ATC patients who cannot undergo surgery. 42 …”

Section: I Seed Implantation Combined With Molecular Targeted Drugsmentioning

confidence: 99%

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies, and it is rapidly falling without any effective therapeutic options. Although radical surgery, radiotherapy, and chemotherapy are performed on patients, the curative effect is suboptimal, and the survival rate is still poor. The discovery of altered gene pathways involved in this aggressive disease has advanced, but molecular targeted drugs targeting these pathways are still in clinical trials. To date, there is no effective way to treat this disease, so it is particularly urgent to find new treatments. At present, multimodal therapy is gradually being applied in clinical practice, which provides a new possibility for prolonging the survival time and improving the prognosis of anaplastic thyroid carcinoma. In this study, we retrospectively analyzed the current clinical multimodal therapy for patients with anaplastic thyroid cancer to evaluate its effect on improving the survival of patients with anaplastic thyroid cancer at different stages.

show abstract

A Novel Multimodal Therapy for Anaplastic Thyroid Carcinoma: 125I Seed Implantation Plus Apatinib After Surgery

Cited by 10 publications

References 34 publications

Anaplastic thyroid cancer: genome-based search for new targeted therapy options

Anaplastic thyroid cancer: genome-based search for new targeted therapy options

Preoperative neoadjuvant targeted therapy with apatinib for inoperable differentiated thyroid cancer

Combination of Novel Therapies and New Attempts in Anaplastic Thyroid Cancer

Contact Info

Product

Resources

About